EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Amneal Pharmaceuticals's enterprise value is $4,325 Mil.
Amneal Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,394 Mil. Therefore, Amneal Pharmaceuticals's EV-to-Revenue for today is 1.81.
The historical rank and industry rank for Amneal Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
AMRX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.22 Med: 1.7 Max: 5.03
Current: 1.81
During the past 8 years, the highest EV-to-Revenue of Amneal Pharmaceuticals was 5.03. The lowest was 1.22. And the median was 1.70.
AMRX's EV-to-Revenue is ranked better than 60.39% of 1025
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs AMRX: 1.81
As of today (2024-04-25), Amneal Pharmaceuticals's stock price is $6.05.
Amneal Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $13.94. Therefore, Amneal Pharmaceuticals's PS Ratio for today is 0.43.
Amneal Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Amneal Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amneal Pharmaceuticals's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's EV-to-Revenue falls into.
Amneal Pharmaceuticals's current Enterprise Value is $4,325 Mil.
Amneal Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,394 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals's share price for today is $6.05.
Amneal Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Amneal Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Amneal Pharmaceuticals (Amneal Pharmaceuticals) Business Description
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMRX has been successfully added to your 